Stifel on Neumora Therapeutics (NMRA): 'lack conviction' in Kora mechanism, but risk/reward 'highly upside biased'
Tweet Send to a Friend
Stifel analyst Paul Matteis reiterated a Hold rating and $3.00 price target on Neumora Therapeutics (NASDAQ: NMRA)The analyst commented, "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
